Investment Counselors of Maryland LLC continued to hold its position in shares of Laboratory Corporation of America Holdings (NYSE:LH) during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,302 shares of the medical research company’s stock at the end of the second quarter. Investment Counselors of Maryland LLC’s holdings in Laboratory Corporation of America Holdings were worth $201,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of the company. CFO4Life Group LLC acquired a new position in shares of Laboratory Corporation of America Holdings during the first quarter worth about $312,000. Oxford Asset Management increased its position in shares of Laboratory Corporation of America Holdings by 68.6% in the first quarter. Oxford Asset Management now owns 51,622 shares of the medical research company’s stock worth $7,406,000 after buying an additional 21,003 shares during the last quarter. Raymond James Financial Services Advisors Inc. increased its position in shares of Laboratory Corporation of America Holdings by 2.1% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 9,900 shares of the medical research company’s stock worth $1,420,000 after buying an additional 199 shares during the last quarter. Elkfork Partners LLC increased its position in shares of Laboratory Corporation of America Holdings by 2.4% in the first quarter. Elkfork Partners LLC now owns 12,936 shares of the medical research company’s stock worth $1,856,000 after buying an additional 308 shares during the last quarter. Finally, Toronto Dominion Bank increased its position in shares of Laboratory Corporation of America Holdings by 55.5% in the first quarter. Toronto Dominion Bank now owns 27,613 shares of the medical research company’s stock worth $3,961,000 after buying an additional 9,857 shares during the last quarter. 91.89% of the stock is currently owned by institutional investors and hedge funds.

Laboratory Corporation of America Holdings (NYSE:LH) opened at 158.65 on Monday. The firm has a market capitalization of $16.25 billion, a P/E ratio of 22.22 and a beta of 0.94. Laboratory Corporation of America Holdings has a 52-week low of $119.51 and a 52-week high of $164.22. The company has a 50 day moving average price of $151.97 and a 200 day moving average price of $143.06.

Laboratory Corporation of America Holdings (NYSE:LH) last announced its quarterly earnings results on Wednesday, July 26th. The medical research company reported $2.47 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.40 by $0.07. Laboratory Corporation of America Holdings had a net margin of 7.57% and a return on equity of 16.85%. The firm had revenue of $2.50 billion for the quarter, compared to analyst estimates of $2.47 billion. During the same period last year, the business earned $2.36 EPS. Laboratory Corporation of America Holdings’s revenue for the quarter was up 4.9% compared to the same quarter last year. On average, equities analysts forecast that Laboratory Corporation of America Holdings will post $9.50 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece was reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another domain, it was stolen and reposted in violation of US and international copyright and trademark law. The original version of this piece can be accessed at https://www.dailypolitical.com/2017/08/07/investment-counselors-of-maryland-llc-has-201000-stake-in-laboratory-corporation-of-america-holdings-nyselh.html.

LH has been the topic of a number of recent analyst reports. ValuEngine downgraded Laboratory Corporation of America Holdings from a “buy” rating to a “hold” rating in a research report on Saturday, June 3rd. Jefferies Group LLC reduced their price target on Laboratory Corporation of America Holdings from $159.00 to $157.00 and set a “hold” rating on the stock in a research report on Friday, April 28th. Barclays PLC upped their price target on Laboratory Corporation of America Holdings from $182.00 to $183.00 and gave the stock an “overweight” rating in a research report on Thursday, July 27th. Zacks Investment Research downgraded Laboratory Corporation of America Holdings from a “hold” rating to a “sell” rating in a research report on Wednesday, April 19th. Finally, BidaskClub raised Laboratory Corporation of America Holdings from a “hold” rating to a “buy” rating in a research report on Saturday, June 17th. Seven research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $158.42.

In other Laboratory Corporation of America Holdings news, SVP Lance Berberian sold 3,613 shares of Laboratory Corporation of America Holdings stock in a transaction on Monday, May 22nd. The shares were sold at an average price of $139.84, for a total value of $505,241.92. Following the transaction, the senior vice president now directly owns 5,789 shares in the company, valued at $809,533.76. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Glenn A. Eisenberg sold 5,968 shares of Laboratory Corporation of America Holdings stock in a transaction on Tuesday, August 1st. The shares were sold at an average price of $159.46, for a total transaction of $951,657.28. Following the completion of the transaction, the chief financial officer now owns 18,122 shares in the company, valued at $2,889,734.12. The disclosure for this sale can be found here. Insiders have sold a total of 15,573 shares of company stock worth $2,397,952 over the last quarter. 0.90% of the stock is owned by company insiders.

Laboratory Corporation of America Holdings Company Profile

Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Institutional Ownership by Quarter for Laboratory Corporation of America Holdings (NYSE:LH)

Receive News & Ratings for Laboratory Corporation of America Holdings Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corporation of America Holdings and related companies with MarketBeat.com's FREE daily email newsletter.